CA2500888C - Isoquinoline compounds and medicinal use thereof - Google Patents

Isoquinoline compounds and medicinal use thereof Download PDF

Info

Publication number
CA2500888C
CA2500888C CA2500888A CA2500888A CA2500888C CA 2500888 C CA2500888 C CA 2500888C CA 2500888 A CA2500888 A CA 2500888A CA 2500888 A CA2500888 A CA 2500888A CA 2500888 C CA2500888 C CA 2500888C
Authority
CA
Canada
Prior art keywords
isoquinolin
methyl
ethyl
formula
hydroxyl group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2500888A
Other languages
English (en)
French (fr)
Other versions
CA2500888A1 (en
Inventor
Masakazu Fujio
Hiroyuki Satoh
Shinya Inoue
Toshifumi Matsumoto
Yasuhiro Egi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tanabe Pharma Corp
Original Assignee
Mitsubishi Tanabe Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Tanabe Pharma Corp filed Critical Mitsubishi Tanabe Pharma Corp
Publication of CA2500888A1 publication Critical patent/CA2500888A1/en
Application granted granted Critical
Publication of CA2500888C publication Critical patent/CA2500888C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
CA2500888A 2002-10-01 2003-10-01 Isoquinoline compounds and medicinal use thereof Expired - Fee Related CA2500888C (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
JP2002-288833 2002-10-01
JP2002288833 2002-10-01
JP2002-340175 2002-11-22
JP2002340175 2002-11-22
JP2003-109160 2003-04-14
JP2003109160 2003-04-14
PCT/JP2003/012608 WO2004031171A1 (ja) 2002-10-01 2003-10-01 イソキノリン化合物及びその医薬用途

Publications (2)

Publication Number Publication Date
CA2500888A1 CA2500888A1 (en) 2004-04-15
CA2500888C true CA2500888C (en) 2010-07-13

Family

ID=32074144

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2500888A Expired - Fee Related CA2500888C (en) 2002-10-01 2003-10-01 Isoquinoline compounds and medicinal use thereof

Country Status (12)

Country Link
US (3) US7220759B2 (enExample)
EP (1) EP1557414B1 (enExample)
JP (1) JP4520406B2 (enExample)
KR (1) KR100735781B1 (enExample)
CN (1) CN100390164C (enExample)
AT (1) ATE552252T1 (enExample)
CA (1) CA2500888C (enExample)
DK (1) DK1557414T3 (enExample)
ES (1) ES2380917T3 (enExample)
PT (1) PT1557414E (enExample)
TW (1) TW200424188A (enExample)
WO (1) WO2004031171A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100390164C (zh) * 2002-10-01 2008-05-28 三菱制药株式会社 异喹啉化合物及其医药用途
CA2507027C (en) * 2002-11-22 2012-05-08 Mitsubishi Pharma Corporation Isoquinoline compounds and medicinal use thereof
EP2184282B1 (en) 2007-08-10 2014-10-08 Mitsubishi Tanabe Pharma Corporation Novel salt of isoquinoline compound and crystal thereof
TWI499418B (zh) * 2009-05-21 2015-09-11 Nerviano Medical Sciences Srl 異喹啉－１（２ｈ）－酮衍生物
US9173395B2 (en) 2011-07-04 2015-11-03 Bayer Intellectual Property Gmbh Use of substituted isoquinolinones, isoquinolindiones, isoquinolintriones and dihydroisoquinolinones or in each case salts thereof as active agents against abiotic stress in plants
CN103130723B (zh) 2011-11-30 2015-01-14 成都地奥制药集团有限公司 一种多聚(adp-核糖)聚合酶抑制剂
WO2013132253A1 (en) * 2012-03-07 2013-09-12 Institute Of Cancer Research: Royal Cancer Hospital (The) 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use
EP3044221B1 (en) 2013-09-11 2018-02-21 Institute of Cancer Research: Royal Cancer Hospital (The) 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use
AR098776A1 (es) * 2013-12-18 2016-06-15 Chiesi Farm Spa Derivados del isocromeno como inhibidores de las fosfoinositido-3 quinasas
KR102293986B1 (ko) * 2019-10-30 2021-08-26 충남대학교산학협력단 이소퀴놀리논 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 폴리(adp-리보스)폴리머라제-1(parp-1) 관련 질환의 예방 또는 치료용 약학적 조성물
US12496297B1 (en) * 2020-10-23 2025-12-16 Washington University Compositions of autophagy modulating agents and uses thereof
CN113636970B (zh) * 2021-09-13 2023-05-23 河北康泰药业有限公司 一种异吲哚酮的化合物、制备方法及其应用

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1062357A (en) 1912-05-31 1913-05-20 Warschauer Schrauben Und Drahtfabriken Ag Nut-lock.
US1174272A (en) 1915-10-27 1916-03-07 Commw Steel Locomotive-bed.
GB1062357A (en) 1965-03-23 1967-03-22 Pfizer & Co C Quinazolone derivatives
JPS4612454Y1 (enExample) * 1968-07-26 1971-04-30
DE2121031A1 (en) 1971-04-29 1972-11-02 Dr. Karl Thomae Gmbh, 7950 Biberach Base-substd quinazolines - thrombocyte aggregation inhibitors
IT1054655B (it) * 1975-08-27 1981-11-30 Lepetit Spa Derivati condensati del l isochinolina
JPS52156875A (en) 1976-06-23 1977-12-27 Mitsui Toatsu Chem Inc Preparation of novel isoquinolone derivatives
JPS5484597A (en) 1977-12-15 1979-07-05 Yamanouchi Pharmaceut Co Ltd Novel heterocyclic compound and its preparation
JPS6442472U (enExample) 1986-06-14 1989-03-14
US4808595A (en) 1986-12-24 1989-02-28 Merck & Co., Inc. Furopyridine sulfonamides and their opthalmological compositions
JPS6442472A (en) 1987-08-10 1989-02-14 Kanebo Ltd Quinazoline derivative, production thereof and brain function disorder improving agent containing said derivative as active ingredient
DE68920798T2 (de) 1988-08-19 1995-05-18 Warner Lambert Co Substituierte Dihydroisochinolinone und verwandte Verbindungen als Verstärker der letalen Effekte von Bestrahlung und bestimmten Chemotherapeutika; ausgewählte Verbindungen, Analoga und Verfahren.
AU8784698A (en) 1997-08-15 1999-03-08 Johns Hopkins University, The Method of using selective parp inhibitors to prevent or treat neurotoxicity
US6514983B1 (en) 1997-09-03 2003-02-04 Guilford Pharmaceuticals Inc. Compounds, methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage
US20020022636A1 (en) * 1997-09-03 2002-02-21 Jia-He Li Oxo-substituted compounds, process of making, and compositions and methods for inhibiting parp activity
US6635642B1 (en) 1997-09-03 2003-10-21 Guilford Pharmaceuticals Inc. PARP inhibitors, pharmaceutical compositions comprising same, and methods of using same
US6197785B1 (en) * 1997-09-03 2001-03-06 Guilford Pharmaceuticals Inc. Alkoxy-substituted compounds, methods, and compositions for inhibiting PARP activity
WO1999059973A1 (en) * 1998-05-15 1999-11-25 Guilford Pharmaceuticals Inc. Carboxamide compounds, compositions, and methods for inhibiting parp activity
WO2000042025A1 (en) 1999-01-14 2000-07-20 Meiji Seika Kaisha, Ltd. Poly(adp-ribose) polymerase inhibitors consisting of pyrimidine derivatives
KR20010101675A (ko) 1999-01-26 2001-11-14 우에노 도시오 2ｈ-프탈라진-1-온 유도체 및 그 유도체를 유효 성분으로하는 약제
DE19918211A1 (de) 1999-04-22 2000-10-26 Basf Ag Cycloalkylsubstituierte Benzimidazole, deren Herstellung und Anwendung
DE19920936A1 (de) 1999-05-07 2000-11-09 Basf Ag Heterozyklisch substituierte Benzimidazole, deren Herstellung und Anwendung
DE19921567A1 (de) 1999-05-11 2000-11-16 Basf Ag Verwendung von Phthalazine-Derivaten
WO2001079184A1 (en) 2000-04-18 2001-10-25 Sumitomo Pharmaceuticals Company, Limited Substituted piperazine compounds
WO2002044157A2 (en) 2000-12-01 2002-06-06 Iconix Pharmaceuticals, Inc. Parb inhibitors
AUPR201600A0 (en) 2000-12-11 2001-01-11 Fujisawa Pharmaceutical Co., Ltd. Quinazolinone derivative
DE60218458T2 (de) 2001-05-08 2007-11-15 Kudos Pharmaceuticals Ltd. Isochinolinon derivate als parp inhibitoren
EP1396488A1 (en) 2001-05-23 2004-03-10 Mitsubishi Pharma Corporation Fused heterocyclic compound and medicinal use thereof
AUPS019702A0 (en) 2002-01-29 2002-02-21 Fujisawa Pharmaceutical Co., Ltd. Condensed heterocyclic compounds
CN100390164C (zh) * 2002-10-01 2008-05-28 三菱制药株式会社 异喹啉化合物及其医药用途
CA2507027C (en) 2002-11-22 2012-05-08 Mitsubishi Pharma Corporation Isoquinoline compounds and medicinal use thereof
JP4612454B2 (ja) 2005-03-31 2011-01-12 本田技研工業株式会社 ブレーキ制御装置

Also Published As

Publication number Publication date
DK1557414T3 (da) 2012-05-29
CA2500888A1 (en) 2004-04-15
US7459465B2 (en) 2008-12-02
ATE552252T1 (de) 2012-04-15
US20040248931A1 (en) 2004-12-09
EP1557414A1 (en) 2005-07-27
US7220759B2 (en) 2007-05-22
TW200424188A (en) 2004-11-16
US7812178B2 (en) 2010-10-12
JPWO2004031171A1 (ja) 2006-02-02
WO2004031171A1 (ja) 2004-04-15
US20090076276A1 (en) 2009-03-19
US20070161620A1 (en) 2007-07-12
KR20050070024A (ko) 2005-07-05
CN1703410A (zh) 2005-11-30
AU2003268724A1 (en) 2004-04-23
ES2380917T3 (es) 2012-05-21
CN100390164C (zh) 2008-05-28
JP4520406B2 (ja) 2010-08-04
EP1557414B1 (en) 2012-04-04
KR100735781B1 (ko) 2007-07-06
PT1557414E (pt) 2012-04-17
TWI338687B (enExample) 2011-03-11
EP1557414A4 (en) 2007-10-31

Similar Documents

Publication Publication Date Title
US7812178B2 (en) Isoquinoline compound and pharmaceutical use thereof
CA2507027C (en) Isoquinoline compounds and medicinal use thereof
US20040176361A1 (en) Fused heterocyclic compound and medicinal use thereof
JP5411300B2 (ja) 可溶性グアニレートシクラーゼ活性化剤
JP7208931B2 (ja) Ｄｕｂ阻害剤としての活性をもつ置換シアノピロリジン類
JPWO2005115975A1 (ja) アリールアルキルアミン化合物及びその製法
NO305951B1 (no) Kjemiske forbindelser, farmasoeytisk preparat med blodplateaggregeringshemmende egenskaper, samt anvendelse av forbindelsene til fremstilling av henholdsvis en blodplateaggregeringsinhibitor og et farmasoeytisk preparat for behandling eller foreby
WO2020254544A1 (en) New egfr inhibitors
EP1638934B1 (en) 3-aminopyrrolidines as inhibitors of monoamine uptake
MX2007006239A (es) Benzoquinolisinas sustituidas como inhibidores de dipeptidil peptidasa iv (dpp-iv) para tratamiento de diabetes.
KR20230116799A (ko) 신규 이미다졸 아세틸렌 유도체
CA3256325A1 (en) NEW INDAZOLE DERIVATIVES
RU2297411C2 (ru) Изохинолиновые соединения, промежуточные соединения, способы их получения и применение
EP2531487A1 (en) Aryl benzylamine compounds
WO1999052894A1 (en) Nitrogen-containing heterocyclic compounds having antiplatelet aggregation effect and medicinal use thereof
ES2384574T3 (es) Derivado de piperidina o sal farmacéuticamente aceptable del mismo
JPH10500967A (ja) カルシウムチャンネルアンタゴニストとしてのフェノキシアルキル置換ピペリジン、ピロリジン、モルホリンおよびチオモルホリン
WO2025262003A1 (en) Dihydro benzoxazine derivatives
JP2025120684A (ja) 上皮成長因子受容体の阻害剤
HK40067220A (zh) 新egfr抑制剂

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20211001